Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier

Yingwen Hu; Na Liu; Bolin Cheng; Yanan Tan; Lijuan Wen; Hong Yuan; Fuqiang Hu

doi:10.18632/oncotarget.13083

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier

Yingwen Hu _, Na Liu, Bolin Cheng, Yanan Tan, Lijuan Wen, Hong Yuan and Fuqiang Hu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:83258-83269. https://doi.org/10.18632/oncotarget.13083

Metrics: PDF 1446 views | HTML 1806 views | ?

Abstract

Yingwen Hu1,2, Na Liu1, Bolin Cheng1, Yanan Tan1, Lijuan Wen1, Hong Yuan1, Fuqiang Hu1

1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, People’s Republic of China

2Department of Chemistry, Purdue University, West Lafayette, IN 47907, United States of America

Correspondence to:

Fuqiang Hu, email: [email protected]

Keywords: co-delivery, sequential, combined therapy, redox-responsive, drug resistance

Received: January 20, 2016 Accepted: October 13, 2016 Published: November 04, 2016

ABSTRACT

Usage of combination therapies to deliver multiple therapeutics to increase treatment efficacy has shown promising results in the clinic. In an effort to maximize the synergistic effect of co-delivery of a drug and siRNA, we have developed a time-dependent sequential drug delivery system (DDS) based on a disulfide-linked chitosan-based nanocarrier (CS-ss-SA) for the co-delivery of paclitaxel (PTX) and Bcl-2 specific siRNA (siBcl-2). This CS-ss-SA nanocarrier is able to transport both drug and siRNA by entrapment of PTX and adsorption of siRNA on the shell by electrostatic attraction. We show that this nanocarrier transports siRNA into tumor cells via its glycolipid-like spatial structure and releases a hydrophobic model drug, Nile Red 8-11 h later. Next, when siRNA and the hydrophobic drug PTX were co-delivered to tumor cells, a synergistic effect was observed in both cell cycle arrest and cell viability. Ultimately, the co-delivery of PTX and siBcl-2 by CS-ss-SA may prove to be more efficacious and may even help overcome drug resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13083

Publication Alerts

Research Papers:

Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier

Abstract